Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Ioannis Avgerinos,1 Aris Liakos,1,2 Apostolos Tsapas,1–3 Eleni Bekiari1,2 1Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Diabetes Centre, Second Medical Department, Aristotle University of Thessal...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Avgerinos I, Liakos A, Tsapas A, Bekiari E
Format: article
Langue:EN
Publié: Dove Medical Press 2019
Sujets:
Accès en ligne:https://doaj.org/article/e39976d9cd7b4b7fbd4e45ff5994375d
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!